JP2022540922A5 - - Google Patents

Info

Publication number
JP2022540922A5
JP2022540922A5 JP2022502580A JP2022502580A JP2022540922A5 JP 2022540922 A5 JP2022540922 A5 JP 2022540922A5 JP 2022502580 A JP2022502580 A JP 2022502580A JP 2022502580 A JP2022502580 A JP 2022502580A JP 2022540922 A5 JP2022540922 A5 JP 2022540922A5
Authority
JP
Japan
Prior art keywords
approximately
difluorophenyl
quinoline
radiation
2theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540922A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/042119 external-priority patent/WO2021011641A1/en
Publication of JP2022540922A publication Critical patent/JP2022540922A/ja
Publication of JP2022540922A5 publication Critical patent/JP2022540922A5/ja
Priority to JP2025106721A priority Critical patent/JP2025141974A/ja
Pending legal-status Critical Current

Links

JP2022502580A 2019-07-17 2020-07-15 ソマトスタチンモジュレーターの結晶形態 Pending JP2022540922A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025106721A JP2025141974A (ja) 2019-07-17 2025-06-24 ソマトスタチンモジュレーターの結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875285P 2019-07-17 2019-07-17
US62/875,285 2019-07-17
PCT/US2020/042119 WO2021011641A1 (en) 2019-07-17 2020-07-15 Crystalline forms of somatostatin modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025106721A Division JP2025141974A (ja) 2019-07-17 2025-06-24 ソマトスタチンモジュレーターの結晶形態

Publications (2)

Publication Number Publication Date
JP2022540922A JP2022540922A (ja) 2022-09-20
JP2022540922A5 true JP2022540922A5 (enExample) 2023-07-10

Family

ID=74211310

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022502580A Pending JP2022540922A (ja) 2019-07-17 2020-07-15 ソマトスタチンモジュレーターの結晶形態
JP2025106721A Pending JP2025141974A (ja) 2019-07-17 2025-06-24 ソマトスタチンモジュレーターの結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025106721A Pending JP2025141974A (ja) 2019-07-17 2025-06-24 ソマトスタチンモジュレーターの結晶形態

Country Status (4)

Country Link
US (2) US12617767B2 (enExample)
EP (1) EP3999509A4 (enExample)
JP (2) JP2022540922A (enExample)
WO (1) WO2021011641A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017296392B2 (en) 2016-07-14 2020-09-24 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3999509A4 (en) 2019-07-17 2023-07-19 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
JP7796115B2 (ja) * 2020-09-09 2026-01-08 クリネティックス ファーマシューティカルズ，インク． ソマトスタチン調節因子の製剤
AU2022281327A1 (en) * 2021-05-25 2023-12-14 Crinetics Pharmaceuticals, Inc. Uses of a somatostatin modulator for the treatment of disease
KR20240132451A (ko) * 2022-01-11 2024-09-03 크리네틱스 파마슈티칼스, 인크. 카르시노이드 증후군의 치료를 위한 소마토스타틴 조절제의 용도
CA3258700A1 (en) 2022-06-10 2023-12-14 Assia Chemical Industries Ltd. SOLID FORMS OF PALTUSOTINE AND THEIR PREPARATION METHOD
AU2024242719A1 (en) 2023-03-28 2025-09-25 Crinetics Pharmaceuticals, Inc. Compositions and methods for administering paltusotine to patients with hepatic impairment
CN117263966A (zh) * 2023-09-19 2023-12-22 上海凌凯医药科技有限公司 一种硼酸衍生物的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
PL372295A1 (en) 2002-02-04 2005-07-11 F.Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
WO2005024416A1 (en) 2003-09-05 2005-03-17 Binghe Wang Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
US7563821B2 (en) * 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
AU2007217474A1 (en) 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
CA2644850A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
US20090258853A1 (en) 2006-03-13 2009-10-15 Brian Eastman Somatostatin Agonists
US8871728B2 (en) 2007-06-29 2014-10-28 Georgia Tech Research Corporation Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
RS56894B1 (sr) 2008-08-13 2018-04-30 Vertex Pharma Farmaceutska kompozicija n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje
JP5564045B2 (ja) 2008-09-02 2014-07-30 ノバルティス アーゲー 二環式キナーゼ阻害剤
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
US9120749B2 (en) 2010-07-30 2015-09-01 Oncotherapy Science, Inc. Quinoline derivatives and MELK inhibitors containing the same
CA2809263A1 (en) 2010-08-27 2012-03-01 Eleni Dokou Pharmaceutical composition and administrations thereof
WO2012151567A1 (en) 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza
WO2012162254A1 (en) 2011-05-23 2012-11-29 Elan Pharmaceuticals, Inc. Inhibitors of lrrk2 kinase activity
EP2715754B1 (en) 2011-05-31 2015-07-29 Linak A/S Actuator
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
DE102011113749A1 (de) * 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
US20140228417A1 (en) 2011-10-05 2014-08-14 Mapi Pharma Ltd. Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
HK1211289A1 (en) 2012-08-06 2016-05-20 Savira Pharmaceuticals Gmbh Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
EP2895150A1 (en) 2012-09-11 2015-07-22 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
HK1213887A1 (zh) 2012-10-16 2016-07-15 Janssen Pharmaceutica N.V. RORγt的苯基连接的喹啉基调节剂
AU2014306451B2 (en) 2013-08-16 2019-01-17 Duke University Substituted hydroxamic acid compounds
CA2925651A1 (en) 2013-09-30 2015-04-02 Ono Pharmaceutical Co., Ltd. Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
CA2943643A1 (en) 2014-03-24 2015-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
HK1255074A1 (zh) 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. 生长抑素调节剂及其用途
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
DK3368534T3 (da) 2015-10-30 2021-02-15 Neurocrine Biosciences Inc Valbenazin-ditosylat og polymorfer deraf
EP3374350B1 (en) 2015-11-09 2022-01-05 Forge Therapeutics, Inc. Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
EP3481825A1 (en) * 2016-07-07 2019-05-15 Plantex Ltd. Solid state forms of palbociclib dimesylate
AU2017296392B2 (en) 2016-07-14 2020-09-24 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
NZ757081A (en) 2017-03-16 2023-03-31 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
WO2018208987A2 (en) 2017-05-10 2018-11-15 Forge Therapeutics, Inc. Antibacterial compounds
EP3664778B1 (en) 2017-08-11 2022-05-25 Merck Patent GmbH Pharmaceutical preparation comprising 3-fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1 h-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile
EP3740475B1 (en) 2018-01-17 2022-04-20 Crinetics Pharmaceuticals, Inc. Process of making somatostatin modulators
TWI852944B (zh) 2018-09-18 2024-08-21 美商克林提克斯醫藥股份有限公司 生長抑制素(somatostatin)調節劑及其用途
EP3999509A4 (en) 2019-07-17 2023-07-19 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
JP7796115B2 (ja) 2020-09-09 2026-01-08 クリネティックス ファーマシューティカルズ，インク． ソマトスタチン調節因子の製剤
AU2022281327A1 (en) 2021-05-25 2023-12-14 Crinetics Pharmaceuticals, Inc. Uses of a somatostatin modulator for the treatment of disease

Similar Documents

Publication Publication Date Title
JP5411734B2 (ja) １−４−（５−シアノインドール−３−イル）ブチル−４−（２−カルバモイルベンゾフラン−５−イル）ピペラジン塩酸塩の多形相
JP5129132B2 (ja) ４−メチル−ｎ−［３−（４−メチル−イミダゾル−１−イル）−５−トリフルオロメチル−フェニル］−３−（４−ピリジン−３−イル−ピリミジン−２−イルアミノ）−ベンズアミドの塩
TWI406661B (zh) ４-甲基-ｎ-〔３-（４-甲基-咪唑-１-基）-５-三氟甲基-苯基〕-３-（４-吡啶-３-基-嘧啶-２基胺基）-苯甲醯胺之結晶型
TWI642650B (zh) 用於製備喹啉衍生物之方法
KR101348625B1 (ko) 이매티닙 메실레이트의 안정한 결정형 및 그의 제조방법
JP6170146B2 (ja) チロシンキナーゼ阻害剤二マレイン酸塩のｉ型結晶およびその製造法
JP7288904B2 (ja) ビアリールエーテル型キナゾリン誘導体
JP2010521477A (ja) イマチニブメシレート
TWI598346B (zh) Crystallographic polymorphism of 4- [5- (pyridin-4-yl) -1H-1,2,4-triazol-3-yl] pyridine-2-carbonitriles and process for producing the same
JP5086069B2 (ja) 重硫酸アタザナビルおよび新規形態の製造方法
CN101765595A (zh) 制备伏立康唑的方法
JP6556293B2 (ja) 純粋なニロチニブ及びその塩の調製のための方法
WO2025002355A9 (zh) 一种jak2抑制剂的晶型及制备方法
JP6985179B2 (ja) プロリンアミド化合物の製造方法
JPWO2018117267A1 (ja) 置換ピペリジン化合物の塩
EP1598346B1 (en) Process for producing acid adduct salt of polyacidic base compound
JP7704681B2 (ja) センタナファジンの製造方法
JP2021530526A5 (enExample)
TWI518072B (zh) 塔適那偉（ａｔａｚａｎａｖｉｒ）硫酸氫鹽之製法及其新穎的形式
WO2015011659A1 (en) Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
EP3398946B1 (en) Salt of morpholine derivative and crystalline form thereof, as well as preparation method, pharmaceutical composition and use of the same
JPH08283262A (ja) ４−インドリルピペラジニル誘導体
CA3011662A1 (en) An improved process for the preparation of regorafenib
JP2025541772A (ja) ナフチリジン化合物の固体形態
WO2020119772A1 (zh) 盐酸美呋哌瑞多晶型物及其制备方法